STOCK TITAN

Repligen Corporation to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) will present at the Stifel 2023 Healthcare Conference on November 15 and Stephens’ Annual Investment Conference on November 16. CEO Tony J. Hunt will participate in analyst-led discussions at both events, with live webcasts available on Repligen’s Investor Relations website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.

  • Stifel 2023 Healthcare Conference being held November 14-15 in New York City. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Wednesday, November 15, at 8:00 a.m. ET.
  • Stephens’ Annual Investment Conference being held November 14-16 in Nashville. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Thursday, November 16, at 11:00 a.m. ET.

A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a life sciences tools and technology company that develops and markets highly innovative bioprocessing solutions and systems. Our products enable efficiencies in the process of manufacturing a wide range of biological drugs, including: monoclonal antibodies; recombinant proteins; cell and gene therapies; and vaccines. We are inspiring advances in bioprocessing for the customers we serve around the globe; primarily biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, see our website at www.repligen.com and follow us on LinkedIn.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com


FAQ

What conferences will Repligen Corporation present at?

Repligen Corporation will present at the Stifel 2023 Healthcare Conference and Stephens’ Annual Investment Conference.

Who will participate in the analyst-led discussions?

CEO Tony J. Hunt will participate in the analyst-led discussions at both events.

Where can I access the live webcasts of the conference presentations?

The live webcasts will be accessible through Repligen’s Investor Relations website at www.repligen.com.

Repligen Corp

NASDAQ:RGEN

RGEN Rankings

RGEN Latest News

RGEN Stock Data

8.84B
51.95M
6.59%
105.58%
8.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About RGEN

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.